Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to residues 371-655 of human DR6.|
|Storage buffer||PBS with 0.05% BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Western Blot (WB)||2-4 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Suggested positive control: antigen standard for TNFRSF21 (transient overexpression lysate), Daudi, HeLa, or Jurkat.
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptor was recently identified and designated DR6 (for death receptor 6) (1). The extracellular domain of DR6 contains four TNFR-like cysteine rich motifs that are related to those of osteoprotegerin (OPG) (2) and TNFR2 (3) with 36% and 42% amino acid identities, respectively. The death domain of DR6 (amino acids 428-494) located adjacent to the transmembrane domain is most related to TNFR1 (27.2%) and least to DR5 (19.7%) (1).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
BM-018; CD358; Death receptor 6; DR6; MGC31965; TNFR-related death receptor 6; Tumor necrosis factor receptor superfamily member 21; tumor necrosis factor receptor superfamily, member 21
BM-018; CD358; DR6; TNFRSF21; UNQ437/PRO868